GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Cyxone AB (OSTO:CYXO) » Definitions » Net Cash per Share

Cyxone AB (OSTO:CYXO) Net Cash per Share : kr0.04 (As of Mar. 2024)


View and export this data going back to 2016. Start your Free Trial

What is Cyxone AB Net Cash per Share?

Net Cash per Share is calculated as Cash, Cash Equivalents, Marketable Securities minus Total Liabilities minus Minority Interest and then divided by Shares Outstanding (EOP). Cyxone AB's Net Cash per Share for the quarter that ended in Mar. 2024 was kr0.04.

The historical rank and industry rank for Cyxone AB's Net Cash per Share or its related term are showing as below:

OSTO:CYXO' s Price-to-Net-Cash Range Over the Past 10 Years
Min: 1.6   Med: 4.78   Max: 29.54
Current: 3.41

During the past 8 years, the highest Price-to-Net-Cash Ratio of Cyxone AB was 29.54. The lowest was 1.60. And the median was 4.78.

OSTO:CYXO's Price-to-Net-Cash is ranked better than
56.93% of 859 companies
in the Biotechnology industry
Industry Median: 4.16 vs OSTO:CYXO: 3.41

Cyxone AB Net Cash per Share Historical Data

The historical data trend for Cyxone AB's Net Cash per Share can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Cyxone AB Net Cash per Share Chart

Cyxone AB Annual Data
Trend Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22
Net Cash per Share
Get a 7-Day Free Trial 0.87 1.15 0.86 0.35 0.24

Cyxone AB Quarterly Data
Mar19 Jun19 Sep19 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Mar24
Net Cash per Share Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 0.24 0.16 0.09 0.04 0.04

Competitive Comparison of Cyxone AB's Net Cash per Share

For the Biotechnology subindustry, Cyxone AB's Price-to-Net-Cash, along with its competitors' market caps and Price-to-Net-Cash data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Cyxone AB's Price-to-Net-Cash Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Cyxone AB's Price-to-Net-Cash distribution charts can be found below:

* The bar in red indicates where Cyxone AB's Price-to-Net-Cash falls into.



Cyxone AB Net Cash per Share Calculation

In the calculation of a company's Net Cash per Share, assets other than cash and short term investments are considered to be worth nothing. But the company has to pay its debt and other liabilities in full. This is an extremely conservative way of valuation. Most companies have negative Net Cash per Share. But sometimes a company's price may be lower than its net-cash.

Cyxone AB's Net Cash per Share for the fiscal year that ended in Dec. 2022 is calculated as

Net Cash per Share (A: Dec. 2022 )
=(Cash, Cash Equivalents, Marketable Securities-Total Liabilities-Minority Interest)/Shares Outstanding (EOP)
=(29.246-5.581-0)/98.4447
=0.24

Cyxone AB's Net Cash per Share for the quarter that ended in Mar. 2024 is calculated as

Net Cash per Share (Q: Mar. 2024 )
=(Cash, Cash Equivalents, Marketable Securities-Total Liabilities-Minority Interest)/Shares Outstanding (EOP)
=(12.286-4.238-0)/215.926
=0.04

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Cyxone AB  (OSTO:CYXO) Net Cash per Share Explanation

Ben Graham invested in situations where the company's stock price was lower than its net-cash. He assigned some value to the company's other current asset. The value is called Net Current Asset Value (NCAV). One research study, covering the years 1970 through 1983 showed that portfolios picked at the beginning of each year, and held for one year, returned 29.4 percent, on average, over the 13-year period, compared to 11.5 percent for the S&P 500 Index. Other studies of Graham's strategy produced similar results.

You can find companies that are traded below their Net Current Asset Value (NCAV) with our Net-Net screener.


Cyxone AB Net Cash per Share Related Terms

Thank you for viewing the detailed overview of Cyxone AB's Net Cash per Share provided by GuruFocus.com. Please click on the following links to see related term pages.


Cyxone AB (OSTO:CYXO) Business Description

Traded in Other Exchanges
Address
Adelgatan 21, Malmo, SWE, 221 22
Cyxone AB is a clinical biotech company with a portfolio of immunomodulating drugs for the treatment of autoimmune diseases such as multiple sclerosis (MS) and rheumatoid arthritis (RA). The product candidates of the company include T20K and Rabeximod.

Cyxone AB (OSTO:CYXO) Headlines

No Headlines